Suchergebnisse - "Uchino, Junji"

PubPharm (6)

1

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients : The SPIRAL-0 Study

enthalten in: The oncologist | 2022

von Chihara, Y. | Takeda, T. | Goto, Y. | +20

ErratumIn: Oncologist. 2024 Mar 18;:. - PMID 38498842

2

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Okura, N. | Nishioka, N. | Yamada, T. | +19

3

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)

enthalten in: Clinical lung cancer | 2019

von Hiranuma, O. | Uchino, J. | Yamada, T. | +5

4

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment : A Phase II Trial

enthalten in: The oncologist | 2019

von Nakao, A. | Hiranuma, O. | Uchino, J. | +26

5

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

enthalten in: Nature communications | 2019

von Taniguchi, H. | Yamada, T. | Wang, R. | +21

6

Treatment rationale and design of the SPIRAL study : A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment

enthalten in: Medicine | 2018

von Uchino, J. | Nakao, A. | Tamiya, N. | +5

1
[1]